After a decade of manufacturing problems, a U.S. federal court ordered a unit of Wockhardt, one of the largest makers of generic drugs, to refrain from making allegedly adulterated medicines at a facility in Illinois. However, the U.S. subsidiary, Morton Grove Pharmaceuticals, recently decided to discontinue operations at the site, according to court documents.
The move came after the Department of Justice last week filed a lawsuit alleging that Morton Grove failed to have adequate procedures to prevent cross-contamination of equipment, failed to reject batches that used a contaminated ingredient, and also failed to investigate how the contamination occurred.
To settle the lawsuit, Morton Grove entered into a consent decree and, as a result, must stop manufacturing and distributing certain drugs that were found to be adulterated. A medicine is considered adulterated if it fails to conform to standards for quality, strength, and purity. The company must also destroy all medicines that are not deemed medically necessary.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect